Compound Evidence File
#EC-2026-0309
Cabergoline
Filed under Oral Tablets. The bureau holds 133 laboratory returns for this compound from 38 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
38 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 20 Dec 2025 | 18 Jul 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 26 Mar 2026 | 6 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 6 May 2026 | 1 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Jan 2026 | 24 Mar 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 10.0 | 10.0 | 18 May 2026 | 3 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 11 Feb 2026 | 13 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 10.0 | 10.0 | 21 Jan 2026 | 10 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 7 Mar 2026 | 24 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 21 Apr 2026 | 8 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 23 Apr 2026 | 28 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 10.0 | 10.0 | 10.0 | 18 Nov 2025 | 25 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Jul 2026 | 12 Aug 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 24 Dec 2025 | 19 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Dec 2025 | 17 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 11 May 2026 | 4 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 9.9 | 1 Feb 2026 | 1 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 3 Dec 2025 | 1 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Mar 2026 | 26 May 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 28 Feb 2026 | 7 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 3 May 2026 | 27 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Mar 2026 | 26 Apr 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.7 | 7.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.7 | 7.2 | 9.2 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.5 | 7.6 | 9.9 | 21 May 2026 | 21 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.3 | 6.8 | 9.5 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.3 | 6.8 | 9.2 | 21 May 2026 | 21 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 6 | 8.3 | 6.3 | 9.9 | 21 May 2025 | 17 May 2026 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 8.0 | 8.0 | 8.0 | 27 Feb 2025 | 27 Feb 2025 |
| LSPLCASE #VI-2026-0523 | X | 1 | 7.7 | 7.7 | 7.7 | 13 Jun 2025 | 13 Jun 2025 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 7.7 | 7.7 | 7.7 | 25 Apr 2025 | 25 Apr 2025 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 6.9 | 6.9 | 6.9 | 16 Mar 2025 | 16 Mar 2025 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 10 | 6.7 | 5.3 | 9.3 | 17 Dec 2024 | 23 May 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 11 | 6.5 | 4.0 | 8.6 | 13 Feb 2025 | 19 Jan 2026 |
| LN PeptidesCASE #VI-2026-0781 | X | 2 | 6.1 | 5.1 | 7.1 | 20 Jun 2025 | 21 May 2026 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 4.0 | 4.0 | 4.0 | 11 Jun 2025 | 11 Jun 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 2.5 | 2.5 | 2.5 | 13 Jun 2025 | 13 Jun 2025 |
Open any subject to view the batch-level evidence for Cabergoline alone.